Analysts expect Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) to report ($0.29) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s earnings. The lowest EPS estimate is ($0.35) and the highest is ($0.22). Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share posted earnings per share of $0.11 in the same quarter last year, which would indicate a negative year-over-year growth rate of 363.6%. The business is scheduled to announce its next quarterly earnings report on Tuesday, March 6th.

According to Zacks, analysts expect that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will report full-year earnings of $1.39 per share for the current fiscal year, with EPS estimates ranging from $1.30 to $1.46. For the next financial year, analysts anticipate that the company will report earnings of ($0.80) per share, with EPS estimates ranging from ($0.86) to ($0.74). Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last released its quarterly earnings data on Wednesday, November 8th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.13. The company had revenue of $39.68 million for the quarter, compared to analyst estimates of $38.22 million. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a net margin of 44.47% and a return on equity of 33.92%. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.08) EPS.

A number of research analysts recently commented on AVDL shares. Zacks Investment Research lowered shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “hold” rating to a “sell” rating in a research note on Tuesday. BidaskClub lowered shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 21st. Langenberg & Company reiterated a “buy” rating and issued a $30.00 price target (up previously from $27.00) on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in a research note on Thursday, September 7th. Finally, Ladenburg Thalmann Financial Services upped their price target on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from $27.00 to $30.00 in a research note on Thursday, September 7th. Two equities research analysts have rated the stock with a sell rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $21.75.

In other Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share news, Director Craig R. Stapleton sold 254,265 shares of the business’s stock in a transaction dated Monday, November 27th. The shares were sold at an average price of $9.35, for a total value of $2,377,377.75. Following the completion of the sale, the director now owns 253,413 shares of the company’s stock, valued at approximately $2,369,411.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael S. Anderson acquired 5,000 shares of the business’s stock in a transaction on Thursday, December 7th. The stock was acquired at an average cost of $8.86 per share, with a total value of $44,300.00. The disclosure for this purchase can be found here. 5.07% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of AVDL. PNC Financial Services Group Inc. boosted its holdings in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 2,484.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 10,956 shares of the company’s stock valued at $121,000 after purchasing an additional 10,532 shares during the period. Nine Chapters Capital Management LLC bought a new stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 3rd quarter worth approximately $132,000. Sei Investments Co. lifted its holdings in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 29.5% during the 2nd quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock worth $140,000 after acquiring an additional 2,900 shares during the period. Arrowstreet Capital Limited Partnership bought a new stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 2nd quarter worth approximately $181,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 3rd quarter worth approximately $184,000. 67.75% of the stock is owned by hedge funds and other institutional investors.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) traded up $0.10 during trading on Friday, hitting $8.22. 138,301 shares of the stock traded hands, compared to its average volume of 186,951. The firm has a market cap of $321.88, a price-to-earnings ratio of 4.26 and a beta of 1.34. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a one year low of $7.52 and a one year high of $12.30. The company has a quick ratio of 1.47, a current ratio of 1.53 and a debt-to-equity ratio of 0.01.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://theolympiareport.com/2017/12/27/avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-avdl-expected-to-post-earnings-of-0-29-per-share.html.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share Company Profile

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Get a free copy of the Zacks research report on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with Analyst Ratings Network's FREE daily email newsletter.